secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001628280-24-015247
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology AACR data: onvansertib shows 73% ORR in bev-naive RAS-mutated mCRC vs 19% in bev-exposed
--------------------------------------------------------------------------------

- Bev-naive patients in Phase 1b/2 trial had ORR of 73% vs 19% for bev-exposed; odds ratio 13.64 (p<0.001) and PFS HR 0.21 (p=0.003).
- Onvansertib inhibits hypoxia pathway via HIF1α regulation, reducing tumor vascularization; combo with bevacizumab enhances reduction.
- In RAS WT mCRC PDX models, onvansertib as monotherapy induced stasis/regression in 70% (14/20) of models; combo with cetuximab in 90% (18/20).
- In SCLC cisplatin-resistant PDX models, onvansertib + paclitaxel led to tumor regression lasting 2 months post-treatment.
- CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC to randomize 90 patients to onvansertib 20mg or 30mg plus SoC vs SoC alone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024015247/0001628280-24-015247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024015247/crdf-20240408.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-015247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer